Search

Kymera Therapeutics Inc

Затворен

СекторЗдравеопазване

118 -2.45

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

116.33

Максимум

121.81

Ключови измерители

By Trading Economics

Приходи

8M

-61M

Продажби

31M

65M

EPS

-0.62

Марж на печалбата

-94.171

Служители

273

EBITDA

6M

-61M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+17.88% upside

Дивиденти

By Acuity

Следващи печалби

3.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

1.2B

9.4B

Предишно отваряне

120.45

Предишно затваряне

118

Настроения в новините

By Acuity

50%

50%

125 / 339 Класиране в Healthcare

Kymera Therapeutics Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

17.09.2026 г., 20:07 ч. UTC

Kymera Therapeutics Inc is advancing during Thursday's market session, having reached a session high earlier before pulling back from that peak.

16.09.2026 г., 20:10 ч. UTC

Social Media

Kymera Therapeutics Inc is trading higher as interest grows due to faster-than-expected enrollment in the Phase 2b BROADEN2 study for its drug KT-621.

15.09.2026 г., 23:31 ч. UTC

Kymera Therapeutics Inc shares are lower in after-market hours, continuing a four-session decline amid broader economic concerns from the NY Empire State Manufacturing Index drop.

11.09.2026 г., 19:52 ч. UTC

Kymera Therapeutics Inc is lower today, pulling back from earlier gains amid speculation about Federal Reserve interest rate hikes and broader market trends.

10.09.2026 г., 20:07 ч. UTC

News
Social Media

Wolfe Research upgraded Kymera Therapeutics to Outperform, setting a price target of $180. Shares are trading higher amid increased investor interest.

9.09.2026 г., 20:07 ч. UTC

Kymera Therapeutics Inc shares are lower Wednesday, reflecting broader market pressures amid rising crude oil prices and inflation concerns.

8.09.2026 г., 20:07 ч. UTC

News

Kymera Therapeutics shares are lower amid insider selling, including a recent sale by Brian Adams. The stock has seen a cumulative decline since Friday.

2.09.2026 г., 19:46 ч. UTC

Event
News

Shares rise as JPMorgan raises price target to $140.00.

28.08.2026 г., 20:01 ч. UTC

Kymera Therapeutics Inc shares are lower today, continuing a decline since Thursday. Trading volume is unusually high amid rising U.S. Treasury yields.

27.08.2026 г., 20:02 ч. UTC

News

Kymera Therapeutics Inc shares are lower today, diverging from recent gains amid high trading volume and broader market resilience following a drop in jobless claims.

25.08.2026 г., 20:07 ч. UTC

Kymera Therapeutics shares are higher today, supported by declining oil prices and lower Treasury yields, enhancing overall investor sentiment toward equities.

21.08.2026 г., 19:26 ч. UTC

News
Social Media

Kymera Therapeutics Inc shares are lower during Friday's session despite earlier gains. Analysts maintain a consensus "Moderate Buy" rating with a target of $125.65.

20.08.2026 г., 22:01 ч. UTC

Kymera Therapeutics Inc. shares are higher in after-market trading, supported by a broader upward trend in biotechnology stocks. The price remains above its 20-day moving average.

19.08.2026 г., 20:02 ч. UTC

Correlated Moves

Kymera Therapeutics is rising amid gains in the ARK Genomic Revolution ETF, which increased significantly. The stock is also experiencing high market volume today.

18.08.2026 г., 19:26 ч. UTC

Kymera Therapeutics Inc shares are higher today, recovering from an earlier decline. No specific news was identified to explain the movement.

17.08.2026 г., 19:54 ч. UTC

Kymera Therapeutics Inc shares are trading higher today amid increased volume, maintaining a positive trend since Friday's close despite earlier intraday fluctuations.

14.08.2026 г., 20:06 ч. UTC

Kymera Therapeutics Inc shares are higher today, recovering from an earlier pullback amid a mixed market backdrop following a decline in U.S. retail sales.

12.08.2026 г., 20:01 ч. UTC

Kymera Therapeutics Inc shares are trading higher amid increased activity and unusually high market volume, with no specific news identified to explain the movement.

6.08.2026 г., 19:56 ч. UTC

Kymera Therapeutics Inc shares are lower today, trading near the lower end of their one-month range amid broader market dynamics and inflationary concerns.

5.08.2026 г., 20:02 ч. UTC

Social Media
News

Kymera Therapeutics reported a narrower net loss of $61.21 million for Q2 2026, driven by increased collaboration revenue and a price target raise from Stifel to $132.

4.08.2026 г., 20:04 ч. UTC

Correlated Moves

Kymera Therapeutics Inc is rising in Tuesday's session, reflecting bullish sentiment in the biotechnology sector amid a broader market uptrend.

3.08.2026 г., 19:46 ч. UTC

News

Kymera Therapeutics Inc shares are lower amid volatility, following Dimensional Fund Advisors LP's 5% stake reduction and broader market trends in biotechnology.

31.07.2026 г., 20:06 ч. UTC

Correlated Moves

Kymera shares lower amid SPDR S&P Biotech ETF decline.

30.07.2026 г., 19:39 ч. UTC

Kymera Therapeutics Inc shares are higher during Thursday's session, with no specific news identified to explain the price action amid broader market trends.

29.07.2026 г., 19:32 ч. UTC

Macro Event

Kymera Therapeutics shares are higher as the Federal Reserve maintains rates at 3.50%–3.75%. Investors monitor inflation trends and their impact on future policy.

28.07.2026 г., 17:42 ч. UTC

News
Social Media

Shares lower despite Guggenheim's price target increase to $135.

27.07.2026 г., 21:03 ч. UTC

News

Kymera Therapeutics shares are lower in after-market hours following the appointment of Terence Rooney, MD, as Chief Medical Officer, succeeding Jared Gollob, MD.

24.07.2026 г., 18:46 ч. UTC

Kymera Therapeutics Inc. shares are roughly flat as trading fluctuates within a narrow range, reflecting routine activity without specific news.

21.07.2026 г., 19:16 ч. UTC

Kymera Therapeutics Inc is trading higher, supported by broader market strength and optimism in AI stocks, despite a pullback earlier in the session.

20.07.2026 г., 22:16 ч. UTC

Kymera Therapeutics Inc shares are lower in after-market hours. Broader market sentiment is influenced by rising Treasury yields amid interest rate and geopolitical concerns.

Сравнение с други в отрасъла

Ценова промяна

Kymera Therapeutics Inc Прогноза

Ценова цел

By TipRanks

17.88% нагоре

12-месечна прогноза

Среден 139.667 USD  17.88%

Висок 180 USD

Нисък 112 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за Kymera Therapeutics Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

18 ratings

16

Купи

2

Задържане

0

Продай

Настроение

By Acuity

125 / 339 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Среден

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Kymera Therapeutics Inc

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company develops STAT6, a Type 2 inflammation in allergic diseases; and TYK2, a treatment for inflammatory bowel disease, psoriasis, psoriatic arthritis, and lupus. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.